The Weekly Roundup
The NCPA annual survey served up some interesting, but by no means surprising, nuggets. Complaints about DIR fees ranked top on the list of issues that registered concern among pharmacists. Douglas Hoey, NCPA CEO cited other top priorities like “long-standing, PBM-generated challenges” of transparency and preferred pharmacy designations and their impact on independent pharmacists. The Eighth Circuit hasn’t provided much hope, either. It recently handed an appellate decision in Pharmaceutical Care Management Association v. Gerhart to PCMA, effectively describing the much-sought-after transparency pharmacy advocates are pushing as “interference” under ERISA (The Employee Retirement Income Security Act). It was not a good day for independent pharmacy.
Here are few other stories that might be of interest:
- That’s a troubling diagnosis. Reassessment is necessary for asthma patients, as new study finds one-third of patients may not have the condition.
- Three cheers for LTC pharmacy advocacy. FDA repackaging guidance draws praise.
- I’ve got a new letter-writing campaign for you. The FDA commissioner neglects the role of pharmacists in his seven recommended policy priorities to reduce impacts of opioid misuse.
- The jury’s out. Small studies are at odds on the interaction of linezolid and warfarin.
- Here’s a look at an international coalition that has committed to speeding vaccine development for MERS, Lassa fever, and Nipah virus.
[Editor’s note:] Our inboxes are stuffed with newsletters and our coffee tables stacked with magazines and industry digests. I’m sure yours are, too. So we’ve decided to run a weekly sampling of interesting stories, issues coverage, and business ideas we come across each week. We hope you’ll share some of your favorites, too. Drop us a line at email@example.com.